-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 24, 2020, Shanghai Kasai Biotechnology Co.
, Ltd.
(hereinafter referred to as "Kasai Bio") received the first round of inquiries from the Shanghai Stock Exchange Science and Technology Innovation Board and completed the reply
.
One hundred secrets and one sparse open a long ten-year rights protection road
One hundred secrets and one sparse open a long ten-year rights protection roadLooking back at the beginning and end of this patent dispute case, the main point of contention between Kasai Biotech and Shandong Hanlin lies in the ownership of 10 long-chain dibasic acid industrialization technology patents
.
For innovative (technological) enterprises, the right carrier of the technological achievements produced by R&D investment is intellectual property rights, and intellectual property protection is very important for the company's future market benefits
.
But fortunately, under the ten-year persistence and efforts of Kasai Bio, after the first trial, the final trial and the retrial by the Supreme Court, Kasai won the case, and the ownership of the 10 patents/patent applications involved all belonged to Kasai, there is no ownership dispute at present, and the confirmation of ownership has also strengthened the intellectual property protection barriers of Kasai Bio in the core technology of long-chain dibasic acid
.
In-depth research in the field of biotechnology reflects the first-class level of scientific research ingenuity
In-depth research in the field of biotechnology reflects the first-class level of scientific research ingenuityKasai Bio is a high-tech enterprise engaged in the research and development, production and sales of new bio-based materials based on synthetic biology and other disciplines, using bio-manufacturing technology
.
It is understood that long-chain dibasic acids have been biotransformed in biological laboratories as early as more than 20 years ago, but due to technical bottlenecks, low output rates, high costs and substandard product quality, industrialization cannot be achieved
.
In addition, it is worth mentioning that the bio-based materials that Kasai Bio are mainly targeting have not only commercial value, but also strong scientific value and social significance
.
![2,2'-([1,1'-biphenyl]-4,4'-diyldivinylene)bis(benzenesulphon...](https://file.echemi.com/fileManage/upload/cas/7/598b2e35-be55-49b2-b221-2aa5c89c59ce.gif)
